↓ Skip to main content

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation

Overview of attention for article published in The Journal of Headache and Pain, September 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

policy
1 policy source
twitter
18 X users

Citations

dimensions_citation
98 Dimensions

Readers on

mendeley
137 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
Published in
The Journal of Headache and Pain, September 2018
DOI 10.1186/s10194-018-0921-8
Pubmed ID
Authors

Lars Bendtsen, Simona Sacco, Messoud Ashina, Dimos Mitsikostas, Fayyaz Ahmed, Patricia Pozo-Rosich, Paolo Martelletti

Abstract

OnabotulinumtoxinA is being increasingly used in the management of chronic migraine (CM). Treatment with onabotulinumtoxinA poses challenges compared with traditional therapy with orally administered preventatives. The European Headache Federation identified an expert group that was asked to develop the present guideline to provide recommendations for the use of onabotulinumtoxinA in CM. The expert group recommend onabotulinumtoxinA as an effective and well-tolerated treatment of CM. Patients should preferably have tried two to three other migraine prophylactics before start of onabotulinumtoxinA. Patients with medication overuse should be withdrawn from the overused medication before initiation of onabotulinumtoxinA if feasible, if not onabotulinumtoxinA can be initiated from the start or before withdrawal. OnabotulinumtoxinA should be administered according to the PREEMPT injection protocol, i.e. injecting 155 U-195 U to 31-39 sites every 12-weeks. We recommend that patients are defined as non-responders, if they have less than 30% reduction in headache days per month during treatment with onabotulinumtoxinA. However other factors such as headache intensity, disability and patient preferences should also be considered when evaluating response. Treatment should be stopped, if the patient does not respond to the first two to three treatment cycles. Response to continued treatment with onabotulinumtoxinA should be evaluated by comparing the 4 weeks before with the 4 weeks after each treatment cycle. It is recommended that treatment is stopped in patients with a reduction to less than 10 headache days per month for 3 months and that patients are re-evaluated 4-5 months after stopping onabotulinumtoxinA to make sure that the patient has not returned to CM. Questions regarding efficacy and tolerability of onabotulinumtoxinA could be answered on the basis of scientific evidence. The other recommendations were mainly based on expert opinion. Future research on the treatment of CM with onabotulinumtoxinA may further improve the management of this highly disabling disorder.

X Demographics

X Demographics

The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 137 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 137 100%

Demographic breakdown

Readers by professional status Count As %
Other 18 13%
Researcher 16 12%
Student > Master 12 9%
Student > Ph. D. Student 10 7%
Student > Bachelor 8 6%
Other 21 15%
Unknown 52 38%
Readers by discipline Count As %
Medicine and Dentistry 43 31%
Neuroscience 12 9%
Pharmacology, Toxicology and Pharmaceutical Science 10 7%
Nursing and Health Professions 4 3%
Biochemistry, Genetics and Molecular Biology 2 1%
Other 7 5%
Unknown 59 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2022.
All research outputs
#2,572,772
of 25,182,110 outputs
Outputs from The Journal of Headache and Pain
#337
of 1,514 outputs
Outputs of similar age
#51,625
of 347,655 outputs
Outputs of similar age from The Journal of Headache and Pain
#15
of 39 outputs
Altmetric has tracked 25,182,110 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,514 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.4. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 347,655 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.